NCT04225299: A trial that was reported late by Steba Biotech S.A.
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT04225299 |
|---|---|
| Title | An Evaluation of the Efficacy of Partial Gland Ablation (PGA) With TOOKAD® Vascular Targeted Photodynamic Therapy (VTP) Versus Active Surveillance for Men With Intermediate Risk Localized Prostate Cancer |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 31, 2020 |
| Completion date | March 31, 2030 |
| Required reporting date | March 31, 2031, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Nov. 16, 2020 |
| Days late | None |